Selective procedures for the synthesis of 6-and of 7-monosubstituted derivatives of pyrazinoI2,3-~I-l ,2,6-thiadiazine 2,2-dioxide and their reactions with N-bromosuccinimide are reported. The structures of the compounds are discussed on the basis of 1 H -, 13C_ NMR and UV spectroscopic data. The pKa values of the compounds have also been determined.
Introduction
PyrazinoI2,3-~I-l ,2,6-thiadiazine 2,2-dioxides are a group of heterocycles which can be regarded as S02 analogs of pteridines. Their synthesis usually involves condensation of an appropriate o-diaminothiadiazine with a carbonyl compound and thus, 6,7-disubstituted and 7-oxo derivatives have been obtained from symmetrical t ,2-dicarbonyl compounds (1) and a-ketoacid esters (2) respectively. As in the related pteridine series, problems regarding regioselectivity arise when using unsymmetrical 1 ,2-dicarbonyl compounds (3) and thus, mixtures of the 6-and 7-substituted isomers are to be expected.
In this paper, we report selective procedures for the synthesis of 6-and of 7-monosubstituted derivatives of pyrazinoI2,3-~lthiadiazines and their reaction with N-bromosuccinimide (NBS) to give the corresponding bromo compounds, versatile intermediates for further structural modifications by nucleophile displacement. 1) To whom correspondence should be addressed. The first reaction studied was that between 3,4,5-triamino-2tJ-l ,2,6-thiadiazine t,t-dioxide (1) (4) and a-aldehydoketones. In principle, the more reactive aldehydo carbonyl group would react with the 4-amino group and afford 7-substituted derivatives. However, when 1 was treated with phenyl glyoxal in water/hydrochloric acid a mixture of the 6-phenyl and 7-phenyl derivatives (2 and 3) was isolated. Even in the presence of sodium bisulfite, which might be expected to complex preferentially with the aldehydo group and thereby, afford the 6-phenyl isomer [as it does in some pteridine synthesis (3)] a mixture was obtained.
When the reaction between the triaminothiadiazine 1 and phenylglyoxal was carried out in acetic acid only the 7-phenyl derivative 3 was formed. Under none of the conditions studied was it possible to obtain preferentially the 6-phenyl derivative 2 from phenylglyoxal; nevertheless, this compound was selectively obtained in the reaction of 1 with m-hydroxyiminoacetophenone, based on the two-step condensation of an a-ketocarboxaldoxime with a 5,6-diaminopyrimidine (5) .
On the other hand, condensation of 1 with methylglyoxal dimethyl acetal in water and hydrochloric acid afforded mixtures of the corresponding 6-and 7-methyl derivatives 5 and 6, together with 4-amino-6-methyl-l tI.5tI-imidazoI4,5-~1-1 ,2,6-thiadiazine 2,2-dioxide (4) . This fused five-membered ring, identical in all respects to the compound obtained in the reaction between I and acetaldehyde (6) , is the only product obtained when the condensation is performed in acetic acid. Since triaminothiadiazine 1 and acetic acid do not yield compound 4, a plausible mechanism for its formation must involve nucleophilic addition of the 4-amino group to give the Schiff base of methylglyoxal dimeth ylacetal followed by hydrolysis and oxida ti\e cleavage (see Scheme 1) .
'~'r~ o2L,AN)
The 7-methyl derivative 6 could selectively be obtained by condensation of triaminothiadiazine 1 with methylglyoxal dimethylacetal under argon atmosphere in acetic acid and a few drops of hydrochloric acid in order to cleave the acetal group. In these conditions, the free aldehyde attacks the more reactive 4-amino group affording exclusively the 7-methyl derivative 6.
Reaction of 1 with pyruvaldehyde l-oxime afforded a mixture of the 6-and 7-methyl derivatives 5 and 6 which after crystallization yielded pure 6-methyl compound 5. However, a more selective procedure to obtain 5 is to react 1 with methylglyoxal dimethylPteridines / Vol. 2 / 1990 / No.1 acetal in acetic acid under an argon atmosphere, in order to avoid oxidation to the purine analog 4. Subsequent addition of hydrochloric acid cleaves the acetal grouping and thus affords pure 5 (Scheme 1).
Treatment of the 7-phenyl and 7-methyl pyrazinothiadiazines 3 and 6 \\ith NBS in methanol afforded the corresponding 6-Dr()mO deri\atiw" 7 and 8 in acceptable yields. This method lL) introduce a bro mine atom in the 6-positi o n is not kn o\\'n in the related pteridine series.
This procedure did not \\ o rk so \\ell \\'ith the 6-subs tituted co mpounds and under more drastic conditions complex mixtures together \\'ith starting material were obtained. However, in the case of the 6-phenyl derivative, the 7-methoxy compound 9 could be isolated indicating that bromination must have taken place.
The structures of the newly synthesized compounds have been established based upon analytical and spectroscopic data. The 13C-N MR chemical shifts are gathered in Table 1 . The C-6 signals of the 7-substituted compounds and the C-7 signals of the 6-substituted ones were assigned unequivocally (DEPT 135 ', coupled spectra) and the rest of the signals by comparison with the data of related compounds (7) . With the chemical shifts of the carbons of the pyrazine moiety it was possible to assign structures to the 6-and 7-substituted compounds since C-6 is shielded in relation to C-7 . In agreement with thi s fact, the signals of the protons belonging to C-7 appear in the 'H-NMR spectra at lower field (2. 6 = 9.27; 5, 8 = 8.56) than those corresponding to the 6-position (3,
More information about the predominant molecular species in solution can be gained from the UV spectra which are based on the spectrophotometrically determined pKa values (8) ( Table 2 ). The position of the tautomeric equilibrium can be depicted from the two UV long wavelength absorption bands of the neutral species since the longest band at 400 nm and higher is characteristic for the H-8 tautomer whereas the second band between 340 and 370 nm indicates the presence of the H -1 isomer. This assignment has already been proved by former investigations (1) . It is interesting to note that the tautomeric equilibrium depends to a large ex tent on the substitution in the 6-and 7-position since a comparison of the extinction coefficients of 5 and 6, for example, indicates a higher percentage of the H-l over the H-8 tautomer in the former compound and a n almost equal amount of the two tautomers in the latter isomer. Cation formation takes place only in very strong acidic medium since all these compounds own very weak basic properties as seen from the low basic pKa values. The preferred protonation site seems to be ~-3 fonning a long mesomeric cation species \\ith the H-N (8) group as the electron-dona ting ce nter. Shift o f the tautomeric equilibrium towa rd s this molecular form can be depicted again from the long wavelength absorption bands and their extinction coefficients. Compound 6 obviously exists almost predominantly in one cation form whereas its 6-methyl isomer 5 consists of a 1 : 1 cation mixture .
In the 6-phenyl-(2) and 7-phenyl-(3) series similar considerations are valid. Here, however, the presence of the phenyl substituent at C-7 shifts the equilibrium even more strongly to the H-1 site from steric reasons. Protonation, on the other hand, causes again a pronounced shift of the equilibrium towards the H-8 cation species. Introduction of a bromine atom into the 6-position of 3 and 6 induces further changes by repressing the H-8 tautomers to a much greater extent. Finally, the UV spectrum of 9 clearly supports the H-I tautomeric molecular form.
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Experimental Part
Melting point~ are uncorrected. The UV spectra were recorded with a Perkin-Elmer Lambda 5 instrument. The IH_ and " C-~\fR ~pectra \\ere recorded \\ith a Varian 390 and a Bruker \\'P-SY -80 spectrometer (TMS as internal standard). \Ias~ spectra \\'ere obtained at 70 eV with a VG-12-250 spectrometer.
4-Amino-6-phenyl-8H-pyra~illo :: .3-f -1.:: .6-rhiadia~il/e
2,2-dioxide (2)
A suspension of 1 (1 g, 5.65 mmol) and w-hydroxyiminoacetophenone (1.4 g, 9.46 mmol) in water (35 ml) and methanol (20 ml) with concentrated HCl (0.5 ml) was stirred at room temperature for 24 h . After removal "in vacuo" of the methanol, the precipitate was filtered , washed with chloroform and recrystallized from water: methanol to give 1.28 g (84%), mp. 
A solution of 3 (0.5 g, 1.82 mmol) and NBS (0.35 g, 1.97 mmol) in methanol (50 ml) was stirred at room temperature for 2 h. The solution was evaporated to dryness, treated with water (25 ml), filtered and recrystallized from water : methanol to give 0.5 g (78%), 
4-Amino-6-bromo-7-methyl-l H-py raz inoI2,3-fl-J,2,6-thiadiazine 2 ,2-dioxide (8)
A solution of 6 (0 .28 g, 1.31 mmol) and NBS (0.32 g, 1.80 mmol) in methanol (20 ml) was stirred at room temperature for 6 h. The solution was evaporated to dryness, treated with water (2 ml), filtered and recrystallized from water to give 0.2 g (53%), mp. 
4-Amino-7-methoxy-6-phenyl-l H-pyra zinoI2,3-fl-1,2,6-thiadiazine 2,2-dioxide (9)
A solution of 2 (0.50 g, 1.82 mmol) and NBS (0.35 g, 1.97 mmol) in methanol (75 ml) was stirred at 45°C for 10 h . The solution was evaporated to dryness, treated with water (25 ml) and filtered . The solid was dissolved in methanol, silica gel was added, and the mixture was evaporated to dryness. The resulting powder was added to a silica gel column (70 -230 mesh) and compound 9 was eluted with chloroform/ methanol (15: 1) (1 -6) or the aglycone (7 -9) to achieve biological activity. The structural relationship between the lumazine N-l-nucleosides (10-14) and uridine, thymidine, and their synthetic analogues such as the a ntivirally active 5-iodo- (14), 5-trifluoromethyl- (15), and E-5-(2-bromovinyl)2' -deoxyuridine (16) as well as the 1-~-D-arabinofurano sy lth ymine (17) justifies our intention to extend our former studies in thi s series to newly substituted lumazine derivatives. As potentially interesting candidates appeared the 6-and 7-p-bromophcnyllumazines, which have been ribosylated and modified at the aglycone and carbohydrate moieties by more or less sta ndard reactions.
Results and Discussion
The starting materials for the glycosylation reactions have been synthesized from 5,6-uracildiamine (1) (18) and p-bromophenylgl yoxa l leading in 85% sulfuric acid solution to 6-p-bromophenyllumazine (2) and in an aqueous ammonia-ethanol mixture to the corresponding 7-isomer (3). Ribosylation was achieved by the Hilbert-Johnson-Birkofer procedure (19) converting 2 and 3 respectively first into their trimethylsilyl derivatives 4 and 5 followed by treatment with 1-0-acetyl-2,3,5-tri-O-benzoyl-~-D-ribofuranose (6) in 1,2-dichloro-ethane under trimethylsilyl trifluorosulfonate catalysis (20) . These conditions guarantee a highly regioselective reaction towards N-l substitution and afforded the 6-(7) and 7-p-bromophenyl-l- 
The protected lumazine nucleosides 7 and 11 are subject to easy thiation reactions which proceeded smoothly with P4SIO or Lawesson reagent in boiling dioxane to give the corresponding yellow-coloured 4-thio nucleosides 9 and 13 in excellent yields. The assignment of their structures is derived from comparisons of their UV spectra with that of I-methyl-6,7-diphenyl-4-thiolumazine (21) (17, 18) . Treatment of 8 and 12 with diphenyl carbonate and a catalytic amount of Na-HCO, in DMF at 160 "C (12, 22) led to 6-(17) and 7 -p-bromopheny 1-2.2' -ahydro-l-~-D-arabinofuranosyllumazine (18) , which were hydrolysed by 0.1 N H 2 S0 4 in acetone to the corresponding arabinosides 19 and 20 in good yields .
Physical Properties
The structures of the newly synthesized pteridine nucleosides were assigned and proven by UV and IH_ NMR spectral comparisons with known structural analogues. The small bathochromic shift of the long wavelength absorption band in the UV spectra of 8 and 12 changing from the neutral form to the monoanions is in agreement with former results (10) and indicates clearly the N-1 substitution in these nucleosides ( Table 1 ). The introduction of a thioxo group into the 4-position causes the welJ-known bathochromic shift (21) of the lumazine derivatives and is also associated with an increased acidity of such molecules of about one pKa unit in comparison to the oxo analogue. It is also noteworthy to mention that the 7-p-bromophenyllumazine derivatives exhibit, due to a stronger mesomeric interaction of the 7-substituent with the nucleus, a higher extinction than its 6-substituted counterpart. This fact can help in differentiating between 6-and 7-phenyl-substituted lumazines in general.
Other fine structural features can be depicted from the lH-NMR spectra ( In a mixture of 100 ml of H 2 0 and 100 ml of cone . aqueous ammonia were dissolved 3.55 g (0.025 mol) of 5,6-uracil-diamine (I) and then a solution of 5.69 g (0.03 mol) ofp-bromoglyoxal hydrate in 250 ml EtOH added. The mixture was refluxed for 2 h and after cooling the dark-yellow precipitate (7.5 g) collected.
Recrystallization from DMSO gave 6.79 g (56%) of yellow crystals of m . p. > 300e. UV 
6-(p-Bromophenyl ) -1-(2,3 ,5-tri-O-benzoyl-{3-D-ribofuranosyl)-lurnazine (7)
In 35 ml of hexamethyldisilazane were heated 2.62 g (7.15 mmol) of 2 and a few crystals of ammonium sulfate under reflux for 18 h . The solution was evaporated to dryness, the residue (4) dissolved in dry 1,2-dichloroethane (50 ml) and then a solution of 3.6 g (7.15 mmol) of 1-0-acetyl-2,3,5-tri-O-benzoyl-13-D-ribofuranose (6) in dichlorethane (20 ml) added . The 13 mixture is stirred for 2 h at room temp. after addition of 1.5 ml of trimethylsilyl trifluoromethane sulfonate. The reaction mixture was then partitioned between CH 2 Ch and a dilute aqueous NaHCO, solution. The organic layer was dri ed (Na2S04) and then evaporated to dryness. The residue gave on recrystallization from CHCl, 90% of colorless crystals ofm. p. 238 -239°C. 
6-(p-Bromopheny l ) -I-[3-D-ribofuranosy llurnazine (8)
1. To dry MeOH (100 ml) were added 1.5 g (1.97 mmol) of 7 and 0.4 g of K 2 C0 3 • The mixture was stirred for 18 h at room temp. , then evaporated to dryness, the residue di ssolved in hot water and then acidified to pH 5 by dilute AcOH . The precipitate was filtered off and gave on recrystallization from MeOH 0.81 g (89%) of colorless crystals of m. p . 284°C (decomp.) . 2. In dry MeOH (50 ml) were dissolved 0.03 g of Na and then 0.76 g (0.1 mmol) of compound 7 a dded and stirred for 24 h at room temp. The reaction mixture was evaporated to a small volume (10 ml), H 2 0 (50 ml) added and then extracted several times with ether. The aqueou s layer was treated with dilute AcOH to pH 5 to form a solid . This material was filtered and gave on recrystallization from MeOH 0.3 g (68 % ) of colourless crystals of m. p . 284°C (decomp .). This product was chroma tographically and spectrophotometrically identica l with the previously desc ribed material.
6-(p-Brornopheny l ) -1-( 2,3 ,5-tri-O-ben::oyl-{3-D-ribofuranosyl ) -4-thiolurnazine (9)
1. A mixture of 1.53 g (2 mmol) and 1.3 g (2 .9 mmol) of P 4 S IO was heated under reflux in dry dioxane (50 ml) for 2 h . After cooling was filtered and then the orange filtrate evaporated to dryness. The residue was partitioned between CRCl, and brine solution, the organic extract dri ed over Na2S04, filtered and again evaporated to a yellow solid. Recrystallization from CHCl,/ MeOH gave 1.4 g (92%) of yellow crystals of m. p . 253 -255°C.
C58.54 H3.49 N7.18 Found C 58 .25 H 3.30 N 7.14 2. A mixture of 0.76 g (0.1 mmol) of compund 7and 0.55 g (1.36 mmol) of Lawesson reagent in dry dioxane (30 ml) was refluxed for 48 h. After cooling the suspension was evaporated to dryness and then the residue partitioned between CHCl 3 and brine solution. The organic layer was dried (Na2S04), filtered, evaporated and then the residue recrystallized from CHCL \IeOH to give 0.7 g (90%) of yellow crystals o f m . p . 25~C. Mixed m . p. , UV and lH-NMR spectra are identical with the previously described materi~ll.
0-{'-Broll1opheny l ) -I-[3-D-ribofuranosy l-4-thioluma-
::ille (10 ) In dry MeOH (40 ml) was stirred 0.56 g (0.7 mmol) of 9 and 0.13 g of K 2 C0 3 for 20 h at room temp. The mixture was evaporated to dryness , the residue dissolved in warm H 2 0 and then acidified to pH 5 with dilute AcOH to give 0.29 g (88 % ) of yellow crystals of m . p. 260°C (decomp. 
7-( p-Bromopheny l ) -1-( 2 ,3 ,5-tri-O-benz oy l-[3-D-ribofuranosyl ) -lumazine (11)
A mixture of 2.7 g (7.0 mmol) of 6-(p-bromophenyl)-lumazine (3) and a few crystals of ammonium sulfate was heated in 50 ml of hexamethyldisilazane under reflux for 20 h. The solution was evaporated to dryness after cooling to a solid residue of 5. It was dissolved in dry 1,2-dichloroethane (45 ml) and then a solution of 3.72 g (7 mmol) of 1-0-acetyl-2,3,5-tri-O-benzoyl-ribofuranose (6) in dichlorethane (30 ml) added and followed by the dropwise addition of the catalyst trimethylsilyl trifluoromethanesulfonate (2.5 ml). After stirring for 2 h at room temp., the solution was partitioned between chloroform (50 ml) and an aqueous solution of NaHC0 3 (50 ml). The organic layer was separated, dried over Na2S04, filtered and evaporated to a pale yellowish residue (4.93 g). Recrystallization from chloroform/ MeOH yielded 4. 
7-(p-Bromopheny l ) -1-13-D-ribofuranosy llumaz ine (12)
A solution of 1.0 g (1.3 mmol) of 11 in dry MeOH (50 ml) was stirred at room temp. after addition of 
5-tri-O-benzoy l-[3-D-ribofuranosyl ) -4-thiolumaz ine (13)
A mixture of 1.25 g (1.63 mmol) of 11 and 1.09 g (2.45 mmol) of P4SlO was heated under reflux in dry dioxane (50 m!) for 1.5 h. After cooling the suspension was filtered , the filtrate evaporated to dryness, the residue dissolved in CHCl 3 and then treated with brine solution. The organic layer was dried (Na2S04), filtered, evaporated to dryness and then the yellow residue recrystallized from CHC I 3 / MeOH to give C58.54 H3.49 N7.18 Found C58.39 H3 .51 N7. 16 
7-(p-Bromophenyl) -1-[3-D-ribojitranosyl-4-thiolumaz ine (14)
A mixture of O. 7 g (9 mmol) of 13 and 0.24 g of K 2 C0 3 in dry MeOH (50 ml) was stirred at room temp. for 18 h . It was evaporated, the residue dissolved in warm 
4-Amino-6-(p-hromopheny l ) -1-[3-D-ribofuranosy lpteridin-2 ( J H ) -one (15)
In a pressure vessel were heated 0.8 g (1 mmol of 9 in 25 % methanolic ammonia (50 ml) to 100 D C for 48 h. The reaction solution was treated with charcoal, filtered, the filtrate evaporated to dryness and the residue recrystallized from MeOH to give 0.15 g (34%) of colorless crystals of m. p. 260°C (decomp. 
4-Amino-7-(p-bromophenyl) -1-fJ-D-ribofuranosylpteridin-2(l H ) -one (16)
According to the preceding procedure 0.8 g (1 mmol) of 13 yielded 0.32 g (67%) of a yellowish crystal powder of m. p. 242 D C (decomp.).
CJ7H 16 
2,2' -Anhydro-6-( p-bromophenyl) -1-fJ-D-arabinofuranosyl/umazine (17)
A mixture of 0.5 g (1.1 mmol) of 8, 0.26 g (1.5 mmol) of diphenyl carbonate, and a catalytic amount of NaHC0 3 (10 mg) in dry DMF (15 m\) was heated to 155 -160°C for 20 min. After cooling the solvent was evaporated to dryness and the residue treated with boiling ether and then the precipitate collected. Recrystallization from MeOH yielded 0.22 g (46%) of a colorless crystal powder of m . p. 282 -284°C. (6D-erythro-[1' ,2' ,3' -trihydroxypropyl]-pterin) is produced in large amounts by human monocytes/macrophages in response to activation with interferon gamma in vitro (1). In vivo, measurement of neopterin concentrations in body fluids, e. g., urine or serum, has been widely used as a convenient and sensitive marker for the activation of cellular immunity (2 -4).
Various authors have reported raised neopterin concentrations in urine or serum of patients with malignant tumors. Moreover, high levels of neopterin at 4) Author to whom correspondence should be addressed.
Copyright «-) 1990 Walter de Gruyter . Berlin' New York diagnosis of cancer and/or during follow-up were shown to be significantly associated with poor prognosis (5 -10).
There is a considerable interest to show by more direct methods that raised neopterin concentrations in body fluids of patients with malignant disease are really due to immune activation phenomena. Here we report data cross-sectionally obtained on 24 women with gynaecological carcinomas, in whom urinary neopterin was measured concomitantly with a variety of hematological and immunological variables. By comparison of data from women with newly diagnosed cancer with those from women with malignant disease in a late phase, we attempted to describe immunological changes occurring during course of cancer.
Patients and Methods

Patients
Twenty-four women were included into the study who were patients at the Department of Obstetrics and Gynaecology of the University Hospital ofInnsbruck, Austria. The patients fulfilled the following enrollment criteria: histologically proven carcinoma of the uterine cervix (12 patients), of the ovary (seven patients) or of the endometrium (five patients); and the patients were not receiving any specific therapy at the time of investigation. Thus, there were 14 women in whom the malignant disease was freshly diagnosed, and 10 women who were in a late stage of their disease and were receiving only palliative therapy since at least three months. The mean age of the 14 pretherapeutic women was 64.3 yr (SD 10.5 yr) with a range from 39 to 76 yr, the 10 women with late stage disease were on average 65.3 yr old (SD 10.9 yr) with a range from 47 to 78 yr. According to the staging criteria of the International Federation of Gynaecology and Obstetrics, there were six women with stage I, eight with stage II, seven with stage III and three with stage IV. (Since the aim of this study was a first elucidation of the effect of longstanding malignant disease on neopterin and its associations with other immune parameters, and since the patients did not receive currently any tumor specific medication, the details of prior tumor specific medication of the 10 women with late disease were not analysed in detail).
Immunophenotyping of peripheral blood mononuclear cells ( PBMC)
These analyses were performed at the Department of Internal Medicine of the University of Innsbruck. Venous blood was collected into 20 mL syringes containing heparin as anticoagulant. PBMC were obtained using a density separation (density 1.077 g/cm 3 ) (Percoll' Pharmacia, Uppsala, Sweden) and adjusted to a concentration of 10 7 cells per mL. For the immunophenotyping an indirect immunofluorescence assay with FITC-conjugated goat anti-mouse immunoglobulin antibody was performed. The immunofluorescence analyses were made using a fluorescence activated cell sorter (FACStar, BectonDickinson).
For the present investigation, only the lymphocyte fraction of peripheral blood cells was evaluated. To obtain the number of immunologically relevant HLA-DR + lymphocytes, the number of B lymphocytes as assessed with the antibody B4 (CD19) was subtracted from the entire number of positive cells. Thus, " HLA-DR + lymphocytes" in this paper always refers to this corrected number.
. Determination of neopterin
Concomitantly with collection of blood, first morning urine specimens were obtained from the patients. These were protected from daylight using a tin-foil and stored at -20°C until analysis. The determination of neopterin was performed at the Institute for Medical Chemistry and Biochemistry of the University of Innsbruck. For the analysis, an optimized and automated high performance liquid chromatography technique on reversed phase was used which has been described earlier (3) . Neopterin was quantitated by its native fluorescence at 353 nm excitation and 438 nm emission wavelengths. To correct for physiological variations of urine concentrations, values were related to creatinine which was determined in the same chromatographic run, using its UV absorption at 235 nm. Neopterin concentrations are therefore given in ~mol per mol creatinine.
Normal values
In order to put the observed neopterin data and the results of the immunologic variables in perspective, we report the normal ranges used. For urinary neopterin, the upper limit of normal is slightly age-and sex-dependent and varies between 230 to 250 ~mol neopterin per mol creatinine for women of the age categories under interest. 
Statistical procedures
Due to the preliminary character of the study, Pvalues below 0.10 were assumed to indicate "statistical significance". Statistical tests used were the MannWhitney U-test for comparison of data obtained in pretherapeutic women vs late stage women, linear correlation analysis and Spearman rank correlation analysis. Table 1 summarizes the observations. As can be seen from the selected percentiles shown, for several variables the distributions were distinctly asymmetric.
Results
Since it was the aim of the study to analyse possible effects of longstanding malignancy on immune parameters, data obtained on patients freshly diagnnsed were compared with those obtained on women with long-standing disease by the Mann-Whitney test. The results are shown in Figure 1 (variables for which the level of statistical significance exceeded 0.10 are not shown). Two groups of variables were seen: neopterin concentrations, numbers of HLA-DR + non-B cells and numbers of leukocytes were significantly higher in women with long-standing disease than in patients at primary diagnosis. In contrast, numbers of total and lymphocyte subgroups positive for CD4 and CD3 were significantly lower in women with long-standing disease.
The data were further analysed by correlation analysis. By linear correlation analysis, neopterin showed the strongest correlation with the number of HLA- In the center of each box, the star indicates the median value, the lower and upper limits of the box denote the 25th and 75th percentiles, and the vertical lines indicate the range of observations. For units, see Table 1 .
DR + cells (r = .638; P = 0.0005). Several other variables were also significantly correlated with neopterin (P < .10); these were in order to decreasing strength of correlation, numbers of thrombocytes (r = 
Discussion
Raised concentrations of neopterin are frequently reported in patients with malignancies (3). The finding that this substance is produced by interferon gamma activated human monocytes/macrophages (1) but not by tumor cells themselves pointed to a preactivation state of cell-mediated immunity in cancer patients. The consistent observation by various research groups of a significant association of high neopterin concentrations and poor prognosis (5 -10) is of particular interest not only for patient's management but also for a better founded immunobiological understanding of the interactions taking place between the immune system and a growing tumor.
Our results contribute to this growing body of evidence for the presence of immune activation in cancer patients. Whereas the numbers of circulating lymphocytes were lower in women wi th long-standing disease than in those studied pre therapeutically, the concentrations of neopterin in urine and the number of non-B lymphocytes expressing HLA-DR antigen and blood cells were significantly higher. Neopterin and number of HLA-DR I non-B lymphocytes, both being indicators of immune activation and very likely of endogenous interferon gamma production, were significantly and positively correlated with each other.
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Our data, and previous data on neopterin in cancer patients, indicate that certain immune mechanisms are activated. Indeed, this reasoning is strongly supported by observations in patients with hematological neoplasias showing significantly higher concentrations of endogenous interferon gamma and a significant and positive correlation between interferon gamma and neopterin levels (11) . Neopterin increases do not, however, provide information whether or not the immune response can eventually eliminate the source of immune activation, e. g., tumor cells.
It is well known for a long time that patients with malignant tumors show diminished responsiveness against recall-antigens, and that immune cells derived from these patients are incapable to respond adequately against antigenic or mitogenic stimuli in vitro. Also, in vitro production of interferon gamma by T cells from cancer patients is usually decreased. Thus, there appears to exist an inverse relationship between endogenous interferon gamma production which appears to he raised and the reduced capacity of in vitro production of this Iymphokine in response to antigenic stimulation. We suggest that mechanisms induced by persistently activated immune mechanisms and particularly persistent cytokine production may contribute to immunodeficiency: It is known that immune response to antigenic stimulation requires an appropriate amount of interferon gamma (12) (13) (14) and interleukin 2 (15 , 16) . Both too low and too high doses inhibit development of a proper immune response. The first possibility (too low) is suggested by the observation that anti-interferon gamma antibodies interfere with alloantigen-or tumor antigen-driven immune response (12, 13, 15) . The second situation (too high) is compatible with data by our group showing that simultaneous stimulation of human peripheral blood mononuclear cells with purified protein derivative (PPD) of mycobacteria and exposure to high concentration of interferon gamma diminishes subsequent response to PPD but not to interleukin-2 (17) . Interleukin-2 is required for the autoerine proliferation of T cells, but interferon gamma is synthesized by T cells independently of proliferation (18) . Thus, antigenic stimulation may induce production and release of interferon gamma while later steps of T cell activation and particularly interleukin-2 synthesis may be inhibited.
Besides the consistent notion of high neopterin concentrations in patients with malignant tumors, a strong argument for the presence of immune activation are our findings on the increase of the number of HLA-DR 4 non-B cells which is significantly associated with an increase of neopterin levels. Much evidence has been accrued to indicate that interferon gamma is able to regulate class II histocompatibility antigen expression on many different cell types, including macro phages (1 9 -21).
Besides these effects, persistent immune activation could also be at least partly responsible for some of the other changes in immune parameters that have been observed in thi s study. For example, cytokines may affect the expression of erythroid progenitors and possibly other hematopoietic precursors (22) . This may be partly the cause for, e. g., the decrease of total lymphocytes a nd lymphocyte subsets . This may be true even for variables for which we were unable to detect a significant correlation with neopterin, because the effects may be small and masked by other causes: looking at the average values, our results would be compatible with such effects.
In sum, the results of our study which of course can be regarded only as preliminary, support the view that in patients with active malignant disease early events of cellular immune mechanisms may be activated. The positive correlation between neopterin concentrations and numbers of HLA-DR + cells renders substantial weight to the conclusions drawn from earlier studies that raised neopterin concentrations in tumor patients are not a product of the tumor cells. but rather reflect activation of certain cellular immune mechanisms.
